Joseph O. Moore

11.4k total citations · 1 hit paper
148 papers, 6.6k citations indexed

About

Joseph O. Moore is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Joseph O. Moore has authored 148 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 50 papers in Genetics and 39 papers in Pathology and Forensic Medicine. Recurrent topics in Joseph O. Moore's work include Chronic Lymphocytic Leukemia Research (41 papers), Acute Myeloid Leukemia Research (37 papers) and Lymphoma Diagnosis and Treatment (35 papers). Joseph O. Moore is often cited by papers focused on Chronic Lymphocytic Leukemia Research (41 papers), Acute Myeloid Leukemia Research (37 papers) and Lymphoma Diagnosis and Treatment (35 papers). Joseph O. Moore collaborates with scholars based in United States, Argentina and United Kingdom. Joseph O. Moore's co-authors include Charles A. Schiffer, Bayard L. Powell, Philip Schulman, Deborah Berg, Robert J. Mayer, Jon P. Gockerman, O. Ross McIntyre, Roger B. Davis, George Omura and E Frei and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Joseph O. Moore

142 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

1994 1.0k citations Bayard L. Powell, Joseph O. Moore et al. profile →

Peers

Countries citing papers authored by Joseph O. Moore

Since Specialization

Citations

This map shows the geographic impact of Joseph O. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph O. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph O. Moore more than expected).

Fields of papers citing papers by Joseph O. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph O. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph O. Moore. The network helps show where Joseph O. Moore may publish in the future.

Co-authorship network of co-authors of Joseph O. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph O. Moore. A scholar is included among the top collaborators of Joseph O. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph O. Moore. Joseph O. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New trends in geophysical applications to geothermal exploration and development 2025 ·The Leading Edge ·John McLennan, (unknown), Joseph O. Moore, (unknown), Kevin England	0
2	Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients 2023 ·Blood ·(unknown), Deedra Nicolet, (unknown), Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Geoffrey L. Uy, Wendy Stock, Andrew J. Carroll, John C. Byrd, Ann‐Kathrin Eisfeld, Jatinder K. Lamba	0
3	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma 2013 ·Leukemia & lymphoma ·Danielle M. Brander, David A. Rizzieri, Jon P. Gockerman, Louis F. Diehl, Thomas C. Shea, Carlos M. DeCastro, Joseph O. Moore, Anne Beaven	5
4	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma 2013 ·Cancer Investigation ·(unknown), David A. Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, Cristina Gasparetto	18
5	Chronic Myelogenous Leukemia 2012 ·Journal of the National Comprehensive Cancer Network ·Susan O’Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Steven M. Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla‐Ibarz, Jerald P. Radich, Vishnu Reddy, Neil P. Shah, Paul J. Shami, Benjamin D. Smith, David S. Snyder, Meir Wetzler, Furhan Yunus	20
6	Implementation of management guidelines for chronic myeloid leukemia: perspectives in the United States. 2012 ·Europe PMC (PubMed Central) ·David A. Rizzieri, Joseph O. Moore	10
7	Acute Myeloid Leukemia 2011 ·Journal of the National Comprehensive Cancer Network ·Margaret O’Donnell, (unknown), Jessica K. Altman, Frederick R. Appelbaum, Steven Coutré, Lloyd E. Damon, (unknown), Salil Goorha, Lori J. Maness, Guido Marcucci, P. Maslak, (unknown), Joseph O. Moore, (unknown), Paul J. Shami, (unknown), Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, Eunice S. Wang	53
8	Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study 2010 ·Journal of Clinical Oncology ·Jörge E. Cortes, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina M. Luger, Bimalangshu R. Dey, Gary J. Schiller, Dat C. Pham, Camille N. Abboud, (unknown), (unknown), Abderrahmane Laadem, Karen Seiter	127
9	LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells 2010 ·Leukemia ·Yvonne M. Mowery, J. Brice Weinberg, Margaret Kennedy, (unknown), Joseph O. Moore, Mark C. Lanasa, Jon P. Gockerman, Louis F. Diehl, Salvatore V. Pizzo, Giuseppe Cianciolo, Daphne R. Friedman	5
10	A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia 2009 ·Clinical Cancer Research ·Daphne R. Friedman, J. Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, (unknown), Youwei Chen, Ning Jiang, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Carlos M. DeCastro, Anil Potti, Joseph R. Nevins	28
11	Chronic Myelogenous Leukemia 2009 ·Journal of the National Comprehensive Cancer Network ·Susan O’Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven M. Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq I. Mughal, Javier Pinilla‐Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, Benjamin D. Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz, Meir Wetzler	175
12	Giant Thoracic Liposarcoma Treated with Induction Chemotherapy Followed by Surgical Resection 2009 ·Journal of Thoracic Oncology ·Mark F. Berry, Thomas A. Sporn, Joseph O. Moore, Thomas A. D’Amico	6
13	Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma 2003 ·Surgery ·Shawn D. Safford, Robert E. Coleman, Jon P. Gockerman, Joseph O. Moore, Jerome M. Feldman, George S. Leight, Douglas S. Tyler, John A. Olson	102
14	Cytogenetic and molecular analysis of an unusual case of acute promyelocytic leukemia with a t(15;17;)(q22;q23;q21) 2003 ·Cancer Genetics and Cytogenetics ·Carlos A Tirado, (unknown), (unknown), Joseph O. Moore, Patrick J. Buckley, Timothy T. Stenzel, Barbara K. Goodman	23
15	Burkitt Lymphoma Arising in Organ Transplant Recipients 2003 ·The American Journal of Surgical Pathology ·Jerald Z. Gong, Timothy T. Stenzel, Ellen Bennett, Anand S. Lagoo, Cherie H. Dunphy, Joseph O. Moore, David A. Rizzieri, James Tepperberg, Peter Papenhausen, Patrick J. Buckley	39
16	Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells 1995 ·Leukemia Research ·Paul J. Shami, Joseph O. Moore, Jon P. Gockerman, James W. Hathorn, Mary A. Misukonis, Jason B. Weinberg	52
17	A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy 1989 ·International Journal of Hyperthermia ·Daniel M. Green, Gary V. Burton, Edwin B. Cox, (unknown), Joseph O. Moore, James R. Oleson	20
18	Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults 1987 ·The American Journal of Medicine ·Roger Kurlander, R. Edward Coleman, Joseph O. Moore, Jon P. Gockerman, Wendell Rosse, (unknown)	26
19	The place of fine needle aspiration cytology for the intraoperative diagnosis of pancreatic malignancy. 1984 ·PubMed Central ·M R B Keighley, Joseph O. Moore, H Thompson	9
20	Malignant effusions in recurrent breast cancer. Steroid hormone receptor analysis of effusion fluid derived cells 1980 ·Cancer ·Kenneth S. McCarty, (unknown), James Wortman, Joseph O. Moore, R. Wayne Rundles, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact